These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 7717096)
1. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Finberg JP Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096 [TBL] [Abstract][Full Text] [Related]
2. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine. Lavian G; Finberg JP; Youdim MB Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392 [TBL] [Abstract][Full Text] [Related]
3. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771 [TBL] [Abstract][Full Text] [Related]
4. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Kumagae Y; Matsui Y; Iwata N Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113 [TBL] [Abstract][Full Text] [Related]
5. Chronic effect of the irreversible and reversible selective MAO-A inhibitors on rat pineal melatonin biosynthesis. Oxenkrug GF; Requintina PJ; McIntyre IM; White K J Neural Transm Suppl; 1994; 41():381-4. PubMed ID: 7523585 [TBL] [Abstract][Full Text] [Related]
6. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline. Gerardy J Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567 [TBL] [Abstract][Full Text] [Related]
7. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro]. Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029 [TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998 [TBL] [Abstract][Full Text] [Related]
9. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Haefely W; Burkard WP; Cesura AM; Kettler R; Lorez HP; Martin JR; Richards JG; Scherschlicht R; Da Prada M Psychopharmacology (Berl); 1992; 106 Suppl():S6-14. PubMed ID: 1546143 [TBL] [Abstract][Full Text] [Related]
10. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. Fagervall I; Ross SB J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Youdim MB; Weinstock M Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899 [TBL] [Abstract][Full Text] [Related]
12. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864 [TBL] [Abstract][Full Text] [Related]
13. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I; Youdim MB; Finberg JP J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens. Pepper JP; Baumann MH; Ayestas M; Rothman RB Brain Res Mol Brain Res; 2001 Mar; 87(2):184-9. PubMed ID: 11245920 [TBL] [Abstract][Full Text] [Related]
15. Modification of cerebral cortical noradrenaline release by chronic inhibition of MAO-A. Finberg JP; Pacak K; Goldstein DS; Kopin IJ J Neural Transm Suppl; 1994; 41():123-5. PubMed ID: 7931217 [TBL] [Abstract][Full Text] [Related]
16. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611 [TBL] [Abstract][Full Text] [Related]
17. Reversibility of the interaction of CGP 11305 A with MAO A in vivo. Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309 [TBL] [Abstract][Full Text] [Related]
18. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Waldmeier PC; Baumann PA Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533 [TBL] [Abstract][Full Text] [Related]
19. Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex. Finberg JP; Pacak K; Kopin IJ; Goldstein DS Naunyn Schmiedebergs Arch Pharmacol; 1993 May; 347(5):500-5. PubMed ID: 8391652 [TBL] [Abstract][Full Text] [Related]